JO2678B1 - Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease - Google Patents

Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease

Info

Publication number
JO2678B1
JO2678B1 JO2008182A JOP20080182A JO2678B1 JO 2678 B1 JO2678 B1 JO 2678B1 JO 2008182 A JO2008182 A JO 2008182A JO P20080182 A JOP20080182 A JO P20080182A JO 2678 B1 JO2678 B1 JO 2678B1
Authority
JO
Jordan
Prior art keywords
oxidopyridin
carboxamide
parkinson
dichloro
pyridine
Prior art date
Application number
JO2008182A
Other languages
Arabic (ar)
English (en)
Inventor
كلير ديلجورج
جيليز بوجون
كريستين مينيت
فيليب ديلاي-جويت
كريستين رافينت-تريلو
Original Assignee
سانوفي -افنتس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سانوفي -افنتس filed Critical سانوفي -افنتس
Application granted granted Critical
Publication of JO2678B1 publication Critical patent/JO2678B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JO2008182A 2007-04-19 2008-04-17 Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease JO2678B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
JO2678B1 true JO2678B1 (en) 2013-03-03

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2008182A JO2678B1 (en) 2007-04-19 2008-04-17 Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006807A (es) * 2012-11-28 2016-01-14 Sanofi Sa Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
CN122055155A (zh) * 2023-10-12 2026-05-15 美德阿利克斯株式会社 经皮吸收组合物
CN122421966A (zh) * 2023-10-12 2026-07-17 傲拓神经科学公司 用替伐普兰治疗神经精神病症

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
DE60018470T2 (de) * 1999-12-23 2006-02-16 Icos Corp., Bothell Cyclische amp spezifische phosphodiesterase inhibitoren
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
NZ542670A (en) * 2003-03-12 2008-11-28 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
US20070049611A1 (en) * 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
US20100130554A1 (en) 2010-05-27
NZ580482A (en) 2011-10-28
AU2008257322A1 (en) 2008-12-04
MY148092A (en) 2013-02-28
ES2367408T3 (es) 2011-11-03
ATE513548T1 (de) 2011-07-15
ME00935B (me) 2012-06-20
SI2146714T1 (sl) 2011-10-28
TW200911247A (en) 2009-03-16
HRP20110666T1 (hr) 2011-10-31
PL2146714T3 (pl) 2011-10-31
EP2146714A1 (fr) 2010-01-27
MX2009011284A (es) 2009-11-02
CN101663035A (zh) 2010-03-03
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
IL201448A (en) 2014-08-31
CL2008001136A1 (es) 2009-01-16
EA200970970A1 (ru) 2010-02-26
PA8776801A1 (es) 2008-11-19
FR2915100A1 (fr) 2008-10-24
MA31367B1 (fr) 2010-05-03
IL201448A0 (en) 2010-05-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
CN101663035B (zh) 2012-06-20
TWI439269B (zh) 2014-06-01
ZA200907251B (en) 2011-04-28
KR101503942B1 (ko) 2015-03-18
UY31035A1 (es) 2008-11-28
WO2008145841A1 (fr) 2008-12-04
CA2684174C (fr) 2014-02-25
RS51869B (sr) 2012-02-29
FR2915100B1 (fr) 2009-06-05
JP5386478B2 (ja) 2014-01-15
PT2146714E (pt) 2011-09-02
EA019194B1 (ru) 2014-01-30
CA2684174A1 (fr) 2008-12-04
HK1141725A1 (en) 2010-11-19
CY1111840T1 (el) 2015-10-07
AU2008257322B2 (en) 2013-06-13
AR066108A1 (es) 2009-07-22
EP2146714B1 (fr) 2011-06-22
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
PL2323642T3 (pl) Zastosowanie układu EDTA + trometamina lub środków foto-wzmacniających, przyłączonych do ryboflawiny do sieciowania rogówki w leczeniu stożka rogówki lub innych zaburzeń związanych z rozszerzeniem rogówki
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150931A (en) Substituted oxazolidinones and their use
IL206277A0 (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
UA102515C2 (ru) Новая лекарственная форма
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL212413A (en) Use of (s) –2– (3– aminopropyl) –5– (2, 5 – dipluorophenyl) - n– methoxy-n– methyl – 2 – phenyl – 1, 3, 4 – thiadiazole – 3 (2h) - carboxamide In preparing a drug to increase cell death is planned in the patient
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MX2009009361A (es) Nueva forma de dosificacion.
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB201220630D0 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus
WO2008145838A3 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
TW200738229A (en) Memantine for the normalization of visual acuity deficits
TH100428B (th) อุปกรณ์กรอกระดูกสำหรับใช้ในทางทันตกรรม